Related Experiment Video
Updated: Sep 28, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease
Ian A Strohbehn1, Rituvanthikaa Seethapathy, Meghan Lee
1Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Insights
Direct-acting antiviral therapies have made hepatitis C virus (HCV) curable. These effective treatments show high cure rates and good safety profiles in patients with kidney disease, including those with chronic kidney disease (CKD) and end-stage kidney disease (ESKD).
Area of Science:
- Nephrology
- Hepatology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection is prevalent in patients with kidney disease.
- HCV is a risk factor for chronic kidney disease (CKD) progression and increases mortality in dialysis patients.
- Kidney transplant recipients with HCV experience poorer outcomes.
Purpose of the Study:
- To review the impact of direct-acting antiviral (DAA) therapies on patients with kidney disease.
- To highlight the efficacy and safety of curative HCV treatments in CKD, end-stage kidney disease (ESKD), and transplant populations.
Main Methods:
- Review of clinical trial and real-world data on DAA therapies in kidney disease patients.
- Analysis of treatment outcomes, cure rates, and adverse events.
Main Results:
- DAA therapies demonstrate extremely high cure rates for HCV in patients with kidney disease.
- These treatments exhibit favorable safety and adverse event profiles in this vulnerable population.
- Curative HCV therapy positively impacts outcomes for CKD, ESKD, and kidney transplant recipients.
Conclusions:
- Direct-acting antiviral therapies have transformed HCV from a chronic illness to a curable condition for patients with kidney disease.
- Curative HCV treatment offers significant benefits, improving morbidity, mortality, and transplant outcomes in affected individuals.
Abstract:
Through the discovery of direct-acting antiviral therapies over the last decade, hepatitis C virus (HCV) has been transformed from a highly morbid and potentially fatal chronic viral infection to a curable illness. HCV is common in patients with kidney disease, is a risk factor for progression of CKD, is associated with higher morbidity and mortality in patients receiving dialysis, and leads to worse allograft and patient outcomes in recipients of kidney transplants. Clinical trial and real-world data of direct-acting antivirals in patients with kidney disease demonstrate extremely high cure rates and favorable adverse event profiles. This review covers the transformative effects of curative HCV therapies on patients with kidney disease, including patients with CKD, ESKD, and those who have received a kidney transplant.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure

